iSprout Raises ₹60 Crore Debt Funding to Accelerate India-Wide Managed Office Growth

Hyderabad headquartered iSprout, one of India’s fastest-growing providers of managed office solutions, today announced that it has raised ₹60 crore in debt funding from Tata Capital, marking a significant milestone in its growth journey. The capital infusion will be used to accelerate expansion across key Indian metros, strengthen enterprise-grade infrastructure, and enhance its rapidly growing managed office portfolio.

“This investment strengthens iSprout’s position to further expand into the high-growth business hubs, allowing us to capture a larger market share in the flexible workspaces and scale with disciplined, asset-strategic growth. With strong occupancy and a robust pipeline, we are committed to delivering long-term value to our clients, investors, and stakeholders, while accelerating our growth journey, including plans for an IPO in the coming years”, said Sundari Patibandla, Co-founder & CEO, iSprout.

With flexible workspaces now becoming a strategic priority for both domestic and global enterprises, iSprout is witnessing strong demand for customized, fully managed office environments. The new funding enables the company to scale faster to meet this surge while maintaining its commitment to delivering high-quality, design-driven workspaces.

Sreeni Tirdhala, Co-founder & Chief Strategy Officer, said: “We have grown 10x in the last five years, and this investment aligns with our mission to build world-class managed offices. Enterprises and GCCs need flexible, high-performance work ecosystems. This funding reinforces our ability to deliver tech-enabled, future-ready spaces. We’re excited to scale with speed and quality.”

iSprout plans to deploy the capital towards new centers in Indian tier 1 and tier 2 cities, along with upgrades to its technology, workspace customization capabilities, and end-to-end facility management services.

With presence across 9 cities, and 25 state-of-the-art centres, iSprout has a portfolio of 2.5 million sq. ft., including spaces that are currently under rapid development.

About iSprout: iSprout is a leading Indian managed office space provider catering to Global Capability Centers (GCCs), large enterprises, and startups. Known for its vibrant designs, enterprise-ready infrastructure, and comprehensive managed services, iSprout enables businesses to scale quickly without operational complexities. With centers across major Indian cities, iSprout continues to redefine modern office experiences through flexibility, customization, and community-driven engagement. The company is currently present in 9 Indian cities with 25 centers and has a portfolio of 2.5 million sq. ft., including spaces that are currently under development.

Tata Capital Healthcare Fund II Invests Upto $10 Mn in Apex Kidney Care

Investment to help the chain expand its dialysis services across India

Tata Capital Healthcare Fund II (TCHF II), the healthcare focused private equity fund of Tata Capital Ltd., announced that it has invested an amount of upto $10 million in Apex Kidney Care (AKC) for an undisclosed equity stake. AKC is India’s second largest dialysis chain in the country and will utilize the newly infused capital to expand its dialysis services across the country.

India has an estimated 2 mn Chronic Kidney Disease (CKD) Stage -5 patients (kidney function below 15%). There are 0.2mn to 0.22mn CKD-5 patients getting added annually. Currently, ~21mn dialysis sessions are conducted on an annual basis in India, and this is estimated to be an abysmal ~11% of the overall annual need of the country. This indicates a significant need gap caused due to a combination of accessibility, affordability and compliance challenges.

Vamesh Chovatia, Partner, Tata Capital Healthcare Fund II

Speaking on the partnership, Mr. Vamesh Chovatia, Partner, Tata Capital Healthcare Fund II said, “We’re excited to partner with Apex Kidney Care, a leader in the dialysis space in the country. At TCHF II, we take a holistic approach to investing capital and backing companies like AKC that address glaring gaps in healthcare. We look forward to working closely with AKC and making high-quality and cost- effective services available to nephrology patients. We believe India needs many more Apex kind of organisations to deliver dialysis services and effectively address the healthcare need gap in the industry.”

Dr. Jatin Kothari, Co-founder and Director, Apex Kidney Care said, “Today is a milestone in the life story of Apex Kidney Care as we announce our partnership with Tata Capital Healthcare Fund II, a relationship that will strengthen our commitment to revolutionize kidney care in India. This new partnership underscores the value of our business model and our vision in delivering high quality dialysis services. The combined strength promises to open many new avenues to advance the business, and favorably touch the lives of thousands of patients fighting kidney disease. We begin this journey with an immense sense of excitement, energy and confidence to be at the forefront in spearheading the change we want to see for all our patients.”

Indranil Roy Choudhury, CEO, Apex Kidney Care said, “This is a defining moment for us at Apex Kidney Care and we are honoured to be associated with Tata Capital Healthcare Fund II. This association will significantly augment our servicing capabilities and will play a critical role in realizing our mission of creating a kidney care ecosystem for patients – built on compassion, respect, transparency and desired treatment outcomes. Tata Capital Healthcare Fund II's support will help us make dialysis and allied services accessible and affordable to all. We will continue to partner with clinicians both in existing and newer geographies as we embark on our journey to significantly ramp up our existing infrastructure. Delivering the desired treatment outcomes and thus improving patient survival will continue to be our purpose.”

About Tata Capital Limited: Tata Capital Limited, a holistic financial services provider caters to the diverse needs of retail, corporate and institutional customers. Its range of offerings include Consumer Finance, Advisory Services, Commercial Finance, Infrastructure Finance, Microfinance, Project Finance, debt syndication, Investment Banking, Private Equity Advisory and Credit Cards. For more information about Tata Capital, please visit www.tatacapital.com

About Tata Capital Healthcare Fund: (TCHF) is a growth oriented private equity fund focused on the healthcare and lifesciences sector in India. The fund is sponsored by Tata Capital Limited, a subsidiary of Tata Sons Limited. TCHF has raised ~ US$ 200 million across two funds - TCHF I (2012) and TCHF II (2022). Across both the funds, TCHF has invested in 16 companies, and has successfully exited 6 companies thus far. For more information about Tata Capital, please visit www.tatacapitalhealthcarefund.com

About Apex Kidney Care: Apex Kidney Care Pvt. Ltd. (AKC) provides comprehensive kidney care and dialysis services at affordable rates to patients suffering from kidney diseases. AKC runs a chain of worldclass dialysis centres and is one of its kind being launched, owned and managed by group of nephrologists. While AKC commands a leadership position in Western India, today it operates more than 180 centres across 120 cities and is all set to emerge as the most dominant dialysis services brand also providing allied services to patients. For more information about AKC please visit www.apexkidneycare.com.

Tata Capital Plans To Raise $3.38 Bn Mainly Through Debt Instrument

Tata Capital Limited, the Mumbai based financial and investment service provider, is planing to raise 280 billion rupees (US$ 3.38 billion) mainly through debt instruments and bank lines in the current financial year to fund its double-digit credit growth, said a Reuters report citing Rajiv Sabharwal, managing director and CEO of Tata Capital.

In an interview with Reuters, the Tata Capital CEO said, "We try to remain granular and well-spread out on our liabilities whether it is bank funding, NCDs (non-convertible debentures), external commercial borrowing or public debt issue".

Explaining that liabilities will have to match with the company's AUM (assets under management), Sabharwal said, "If credit is expected to grow at around 15%, we will try to grow our AUM (assets under management) by more than 25%."

Stating the company's inclination towards retail sector, Sabharwal further said that the contribution from the retail segment could raise to around 85%, while the remaining 15% will be in corporate.

Tata Capital will deliberately choose companies that are safe and belong to large groups and do not intends to increase its exposure to corporates rated AA and below.

The group's consolidated loan book was 1.28 trillion rupees at the end of June, with more than three-fourths comprising secured loans.

A subsidiary of Tata Sons, Tata Capital offers consumer loans, wealth management, commercial finance, and infrastructure finance, among others.

Tata Capital, registered as NBFC with the RBI, has three subsidiaries – Tata Capital Housing Finance, Tata Capital Financial Services and Tata Cleantech Capital.

Very recently, a subsidiary of Flipkart co-founder Sachin Bansal’s Navi Group, which is also one of the partners of Tata Capital, has been acquired by Ananya Birla’s Svatantra Microfin Private Limited.

Meanwhile, Tata Capital aims to expand its wealth management business, and foray into education financing this year, said Sabharwal to Reuters.

Zaggle Ties with Tata Capital’s Moneyfy Platform to Offer Investment Products to Its 4.5+ Mn Users

The partnership earmarks Zaggle’s foray into offering investment products

Zaggle, a profitable SaaS FinTech company and a pioneer in digitizing business spends, partners with Tata Capital’s digital wealth management platform – Moneyfy. This will greatly benefit Zaggle users, who can now get easy access to a plethora of investment options available on Moneyfy. The partnership also earmarks Zaggle’s foray into offering investment products as part of its expansion strategy.

To begin with, Moneyfy is a comprehensive digital platform which aims to make the process of wealth creation hassle–free and secure. Zaggle’s users will have seamless access to all the mutual funds available on the Moneyfy platform including a host of tax saving funds. To encourage first-time mutual fund customers, investments can start with an amount which is as low as Rs 100. Investing in a mutual fund scheme using Monefy is truly effortless and seamless. Customers can easily invest in a SIP, a NFO or a well-researched MF scheme.

Equipped with intelligent features, Moneyfy enables customers to on-board in minutes. The App’s unique ‘My watchlist’ feature allows customers to track their portfolio on a real time basis.

Going forward, Zaggle will further expand accessibility to all other investment options available on Moneyfy including insurance, loans, fixed deposits, NPS amongst other offerings. Zaggle strives to provide better experience to its customers by expanding its product offerings.

Commenting on this partnership, Raj N, Founder and Chairman, Zaggle, said, “We have always endeavored to provide a seamless experience to all our users by offering them a complete suite of services all under Zaggle. We are excited to join hands with Tata Capital and thereby expand our offerings with the introduction of investment products. With Moneyfy, our users will now get access to best-in-class investment products which will help in their journey of wealth creation.”

Speaking on the tie – up, Saurav Basu, Head – Wealth Management, Tata Capital Ltd. said, “We are delighted to partner with Zaggle to help customers achieve their financial goals. Moneyfy is all about making the process of managing money uncomplicated, transparent and truly enjoyable. Customers across categories can simply customize their plans and choose from a wide range of investment options to meet their objectives. We look forward to a mutually rewarding partnership with Zaggle.”

Zaggle which provides expense management system and employee rewards and recognition program services to companies, has been regularly expanding its product line. Earlier, the company had announced its partnership with EarlySalary to offer affordable and instant lending solutions to its existing clientele. It has witnessed rapid growth journey since its inception in 2011 and aims to tap into the $1 trillion addressable Indian spend management market.

IT Solutions Startup Indusface Gets $5 Mn in Funding from Tata Capital Growth Fund II

Indusface, a start-up providing IT security solutions, has received USD 5 million funding from Tata Capital Growth Fund II.

The funding will be used by Indusface for global customer acquisition and product innovation, Tata Capital said in a release.

"We believe that the cybersecurity market will continue to see significant growth as securing digital assets becomes a priority with the increased salience of digital business processes," Tata Capital Growth Fund's Managing Partner Akhil Awasthi said in the release.

After the transaction, Tata Capital Growth Fund Partner Pramod Ahuja will join the Indusface board.

Indusface solutions help customers in detecting security risks and protect them from being hacked.

TCGF II invests in companies that focus on urbanisation, discrete manufacturing and strategic services. PTI HV

Tata Capital Launches Online Lending Platform for Corporate Borrowing

Tata Capital, the financial services arm of the Tata Group, launched an Online Working Capital Platform for its customers. The newly developed online platform under Tata Capital’s Commercial Finance line of business, aims to provide customers with an easy, seamless and paperless experience. As an industry first, loans up to INR 2 crores can be approved within 24 hours.

Tata Capital’s latest lending platform is one-of-its-kind in the industry which allows customers to access their loan account details, utilize the loan limits anywhere anytime. Customers can avail starting from INR 10 Lacs to as high as INR 2 crores. Tata Capital is today a leading player in the commercial business loan segment catering to a diverse set of customers across India.

Speaking on the launch of the online platform, Kusal Roy, Managing Director, Tata Capital Financial Services Limited, said “The Indian economy is growing at steady pace and we aim to fuel India’s growth story with our customer- centric financial solutions. Our new online working capital platform is designed to make commercial borrowing easier, convenient and super-fast. At Tata Capital, we are committed to empowering our customers through innovation and adding value to their businesses.”

Also Read - Ratan Tata’s RNT Capital To Invest $150 Mn in Alibaba’s Ant Financial

The online working capital lending platform is developed in partnership with Biz2Credit, a US based leading fintech company. Rohit Arora, Co-Founder and CEO, Biz2Credit, stated that “Our partnership with Tata Capital has expanded access to capital for millions of small and mid-sized entrepreneurs in India. Through Biz2Credit’s proprietary technology and Tata Capital’s resources, we are able to help SMEs quickly and easily secure the funding they need to grow.”

Tata Capital’s Commercial Finance Business provides financial solutions for Large, Medium, Small, Emerging Corporates and value based solutions to their ecosystems including Government & Public sector enterprises. The platform can be accessed from the Tata Capital website here.

Pharmaceutical Company Brinton Pharmaceuticals Ltd. Raises $4M from TATA Capital

Brinton Pharmaceuticals Ltd, a leading Indian pharmaceutical company, announced today that TATA Capital Healthcare fund has invested approximately $4 million in the Company, acquiring a minority stake. Brinton has been providing superior healthcare products and services for various therapeutic segments, to meet the unmet medical needs of millions of people.

The investment will support the firm’s entry into newer areas such Pediatric and Gynaecology segments and expand international operations from presently 8 to 32 countries.

Speaking about this investment, Rahul Darda, Managing Director of Brinton Pharmaceuticals Ltd, India said “Dermatology and Cosmeceuticals are among the fastest growing therapeutic segments in Indian Pharmaceutical Market growing at an annual CAGR of 15%. A long-term impact in the field of Research & Development will make newer innovations in the field of dermatology possible and Brinton is at the cusp of this transformation. Brinton has taken a therapy-focused approach towards growth and we believe this partnership with a focused Healthcare fund with Tata Capital is a step towards furthering the company’s growth objectives.”

“We are proud to announce TATA Capital’s investment in Brinton Pharmaceuticals Ltd., within two years of the beginning of commercial operations. This investment is a testimony to the company’s robust and strong foundations. We are optimistic about the future and have a roadmap in place to cross INR 300 Cr in the dermatology segment by FY 2021.” said Vijey Christopher, Sr. Vice President, Brinton Pharmaceuticals Ltd.

“With its strong brand proposition, Brinton Pharmaceuticals is well-poised to make a dent in the Dermatology space and we believe this investment from Tata Capital will further strengthen its wings to aggressively pursue its growth strategies.” said Vijay Datt, founder and CEO Citadel Management Consulting who was exclusive advisor of the transaction.

Brinton Pharmaceuticals Ltd, India was founded in 2013 with the aim of filling the need for affordable, yet high quality pharmaceuticals with world class packaging. Its innovative products are developed by anticipating patient requirements, and in an eco-friendly manner. Within a year, it became one of the fastest growing companies in India in the dermatology segment, despite an already crowded and competitive market. The firm has launched 14 new brands in India.

Since its launch, Brinton Pharmaceuticals’ has witnessed rapid expansion, thanks to its superior customer service and global operational excellence. It has a field workforce of 400 in India, and also spread operations in eight countries majorly Francophone and West Africa, along with Nepal, Sri Lanka and Bangladesh.

As per AWACS, Brinton Pharmaceuticals is the fastest growing pharmaceutical company amongst newly launched companies in last 24 months in all therapeutic segments. Currently, five of Brinton’s brands are ranked in top 5 brands in India.

Headquartered in Pune, India, Brinton Pharmaceuticals has a global presence with registered offices in USA, UK & Ghana.